Pub Date : 2023-03-01DOI: 10.38109/2225-1685-2023-1-6-65
I. Chazova, N. Chikhladze, N. Blinova, Z. Belaya, N. Danilov, E. Elfimova, A. Litvin, L. Y. Rozhinskaya, N. Sviridenko, M. Shvetsov, V. Azizov, E. A. Grigorenko, N. P. Mit’kovskaja, I. Mustafaev, A. Polupanov, A. Sarybaev, G. A. Hamidullaeva
Disclaimer. The EAC Guidelines represent the views of the EAC, and were produced after careful consideration of the scientific and medical knowledge, and the evidence available at the time of their publication. The EAC is not responsible in the event of any contradiction, discrepancy, and/or ambiguity between the EAC Guidelines and any other official recommendations or guidelines issued by the relevant public health authorities, in particular in relation to good use of healthcare or therapeutic strategies. Health professionals are encouraged to take the EAC Guidelines fully into account when exercising their clinical judgment, as well as in the determination and the implementation of preventive, diagnostic, or therapeutic medical strategies; however, the EAC Guidelines do not override, in any way whatsoever, the individual responsibility of health professionals to make appropriate and accurate decisions in consideration of each patient’s health condition and in consultation with that patient and, where appropriate and/or necessary, the patient’s caregiver. Nor do the EAC Guidelines exempt health professionals from taking into full and careful consideration the relevant official updated recommendations or guidelines issued by the competent public health authorities, in order to manage each patient’s case in light of the scientifically accepted data pursuant to their respective ethical and professional obligations. It is also the health professional’s responsibility to verify the applicable rules and regulations relating to drugs and medical devices at the time of prescription.
{"title":"Eurasian clinical guidelines for the diagnosis and treatment of secondary (symptomatic) forms of arterial hypertension (2022)","authors":"I. Chazova, N. Chikhladze, N. Blinova, Z. Belaya, N. Danilov, E. Elfimova, A. Litvin, L. Y. Rozhinskaya, N. Sviridenko, M. Shvetsov, V. Azizov, E. A. Grigorenko, N. P. Mit’kovskaja, I. Mustafaev, A. Polupanov, A. Sarybaev, G. A. Hamidullaeva","doi":"10.38109/2225-1685-2023-1-6-65","DOIUrl":"https://doi.org/10.38109/2225-1685-2023-1-6-65","url":null,"abstract":"Disclaimer. The EAC Guidelines represent the views of the EAC, and were produced after careful consideration of the scientific and medical knowledge, and the evidence available at the time of their publication. The EAC is not responsible in the event of any contradiction, discrepancy, and/or ambiguity between the EAC Guidelines and any other official recommendations or guidelines issued by the relevant public health authorities, in particular in relation to good use of healthcare or therapeutic strategies. Health professionals are encouraged to take the EAC Guidelines fully into account when exercising their clinical judgment, as well as in the determination and the implementation of preventive, diagnostic, or therapeutic medical strategies; however, the EAC Guidelines do not override, in any way whatsoever, the individual responsibility of health professionals to make appropriate and accurate decisions in consideration of each patient’s health condition and in consultation with that patient and, where appropriate and/or necessary, the patient’s caregiver. Nor do the EAC Guidelines exempt health professionals from taking into full and careful consideration the relevant official updated recommendations or guidelines issued by the competent public health authorities, in order to manage each patient’s case in light of the scientifically accepted data pursuant to their respective ethical and professional obligations. It is also the health professional’s responsibility to verify the applicable rules and regulations relating to drugs and medical devices at the time of prescription.","PeriodicalId":11859,"journal":{"name":"Eurasian heart journal","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77442622","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-12-21DOI: 10.38109/2225-1685-2022-4-90-97
E. Blinova, T. A. Sahnova, I. Merkulova, E. Aidu, V. Trunov, R. M. Shahnovich, T. Sukhinina, N. Zhukova, N. Barysheva, I. I. Staroverov
The aim of the work is to evaluate the planarity of the QRS loop and its relationship with systolic dysfunction of the left ventricle in patients in the subacute period of myocardial infarction (MI).Materials and methods. The ECG of 265 patients with a diagnosis of acute myocardial infarction were analyzed. The control group consisted of 55 healthy individuals. The planarity index was calculated as the ratio of the area of the QRS loop projection onto the plane (the polar vector of the QRS loop) and the true area of the QRS loop in space using a synthesized vectorcardiogram.Results. In patients with MI, the planarity index was significantly lower than in healthy individuals: 0,87 [0,71; 0,94] and 0,96 [0,93; 0,97], respectively, p < 0,0001. Weak but significant correlations between the planarity index and the left ventricular ejection fraction (LVEF, r = 0,41, p < 0,001) and with the number of affected segments of the left ventricle according to echocardiography (r = −0,43, p < 0,001) were found. In patients with MI, the planarity index was lower in the presence of pulmonary edema in the acute period of MI (0,68 [0,54; 0,86]; without pulmonary edema 0,88 [0,76; 0,94], p < 0,001), and in the presence of a history of chronic heart failure (0,79 [0,61; 0,88]; without chronic heart failure 0,88 [0,75; 0,94], p = 0,007). In patients with MI of both anterior and inferior localization, the planarity index was significantly lower with LV EF < 50% compared with LV EF ≥ 50%. The planarity index was significantly lower in anterior MI than in inferior MI. Conclusion. In patients in the subacute period of MI, there is a decrease in the QRS loop planarity index, which correlates with the volume of myocardial damage, a decrease in LV EF, and the presence of acute and chronic heart failure. The QRS loop planarity index was significantly lower in anterior MI than in inferior MI.
本研究旨在探讨亚急性期心肌梗死(MI)患者左心室QRS环的平面度及其与收缩功能障碍的关系。材料和方法。对265例急性心肌梗死患者的心电图进行分析。对照组由55名健康个体组成。平面度指数计算为QRS环路投影到平面上的面积(QRS环路的极向量)与空间中QRS环路的真实面积之比。心肌梗死患者的平面度指数明显低于健康人:0,87 [0,71;0,94]和0,96 [0,93;0,97]， p < 0,0001。超声心动图显示，平面度指数与左心室射血分数(LVEF, r = 0,41, p < 0.001)和左心室受影响节段数(r = - 0,43, p < 0.001)之间存在微弱但显著的相关性。心肌梗死患者急性期出现肺水肿时，平面度指数较低(0,68 [0,54;0, 86);无肺水肿0,88 [0,76;0,94]， p < 0.001)，并且存在慢性心力衰竭史(0,79 [0,61;0, 88);无慢性心力衰竭0,88 [0,75;0,94]， p = 0,007)。在前位和下位心肌梗死患者中，左室EF < 50%的平面指数明显低于左室EF≥50%的平面指数。心肌梗死前段的平面度指数明显低于心肌梗死下段。在心肌梗死亚急性期的患者中，QRS环平面度指数下降，与心肌损伤体积、左室EF下降以及急性和慢性心力衰竭的存在相关。心肌梗死前段QRS袢平面度指数明显低于心肌梗死下段。
{"title":"New possibilities of electrocardiography: evaluation of the vectorcardiographic QRS loop planarity in patients with myocardial infarction","authors":"E. Blinova, T. A. Sahnova, I. Merkulova, E. Aidu, V. Trunov, R. M. Shahnovich, T. Sukhinina, N. Zhukova, N. Barysheva, I. I. Staroverov","doi":"10.38109/2225-1685-2022-4-90-97","DOIUrl":"https://doi.org/10.38109/2225-1685-2022-4-90-97","url":null,"abstract":"The aim of the work is to evaluate the planarity of the QRS loop and its relationship with systolic dysfunction of the left ventricle in patients in the subacute period of myocardial infarction (MI).Materials and methods. The ECG of 265 patients with a diagnosis of acute myocardial infarction were analyzed. The control group consisted of 55 healthy individuals. The planarity index was calculated as the ratio of the area of the QRS loop projection onto the plane (the polar vector of the QRS loop) and the true area of the QRS loop in space using a synthesized vectorcardiogram.Results. In patients with MI, the planarity index was significantly lower than in healthy individuals: 0,87 [0,71; 0,94] and 0,96 [0,93; 0,97], respectively, p < 0,0001. Weak but significant correlations between the planarity index and the left ventricular ejection fraction (LVEF, r = 0,41, p < 0,001) and with the number of affected segments of the left ventricle according to echocardiography (r = −0,43, p < 0,001) were found. In patients with MI, the planarity index was lower in the presence of pulmonary edema in the acute period of MI (0,68 [0,54; 0,86]; without pulmonary edema 0,88 [0,76; 0,94], p < 0,001), and in the presence of a history of chronic heart failure (0,79 [0,61; 0,88]; without chronic heart failure 0,88 [0,75; 0,94], p = 0,007). In patients with MI of both anterior and inferior localization, the planarity index was significantly lower with LV EF < 50% compared with LV EF ≥ 50%. The planarity index was significantly lower in anterior MI than in inferior MI. Conclusion. In patients in the subacute period of MI, there is a decrease in the QRS loop planarity index, which correlates with the volume of myocardial damage, a decrease in LV EF, and the presence of acute and chronic heart failure. The QRS loop planarity index was significantly lower in anterior MI than in inferior MI.","PeriodicalId":11859,"journal":{"name":"Eurasian heart journal","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-12-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79381939","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-12-21DOI: 10.38109/2225-1685-2022-4-6-67
S. Golitsyn, M. Kostyukevich, L. Lajovic, N. Mironov, N. Mironova, M. Utsumueva, D. R. Khusyainova, N. Shlevkov, B. C. Bazarov, V. Azizov, E. D. Dzhishambaev, N. Zakirov, D. Goncharik
The EAC Guidelines represent the views of the EAC, and were produced after careful consideration of the scientific and medical knowledge, and the evidence available at the time of their publication. The EAC is not responsible in the event of any contradiction, discrepancy, and/or ambiguity between the EAC Guidelines and any other official recommendations or guidelines issued by the relevant public health authorities, in particular in relation to good use of healthcare or therapeutic strategies. Health professionals are encouraged to take the EAC Guidelines fully into account when exercising their clinical judgment, as well as in the determination and the implementation of preventive, diagnostic, or therapeutic medical strategies; however, the EAC Guidelines do not override, in any way whatsoever, the individual responsibility of health professionals to make appropriate and accurate decisions in consideration of each patient’s health condition and in consultation with that patient and, where appropriate and/or necessary, the patient’s caregiver. Nor do the EAC Guidelines exempt health professionals from taking into full and careful consideration the relevant official updated recommendations or guidelines issued by the competent public health authorities, in order to manage each patient’s case in light of the scientifically accepted data pursuant to their respective ethical and professional obligations. It is also the health professional’s responsibility to verify the applicable rules and regulations relating to drugs and medical devices at the time of prescription.
{"title":"Eurasian association of cardiology (EAC) guidelines for the prevention and treatment of ventricular heart rhythm disorders and prevention of sudden cardiac death (2022)","authors":"S. Golitsyn, M. Kostyukevich, L. Lajovic, N. Mironov, N. Mironova, M. Utsumueva, D. R. Khusyainova, N. Shlevkov, B. C. Bazarov, V. Azizov, E. D. Dzhishambaev, N. Zakirov, D. Goncharik","doi":"10.38109/2225-1685-2022-4-6-67","DOIUrl":"https://doi.org/10.38109/2225-1685-2022-4-6-67","url":null,"abstract":"The EAC Guidelines represent the views of the EAC, and were produced after careful consideration of the scientific and medical knowledge, and the evidence available at the time of their publication. The EAC is not responsible in the event of any contradiction, discrepancy, and/or ambiguity between the EAC Guidelines and any other official recommendations or guidelines issued by the relevant public health authorities, in particular in relation to good use of healthcare or therapeutic strategies. Health professionals are encouraged to take the EAC Guidelines fully into account when exercising their clinical judgment, as well as in the determination and the implementation of preventive, diagnostic, or therapeutic medical strategies; however, the EAC Guidelines do not override, in any way whatsoever, the individual responsibility of health professionals to make appropriate and accurate decisions in consideration of each patient’s health condition and in consultation with that patient and, where appropriate and/or necessary, the patient’s caregiver. Nor do the EAC Guidelines exempt health professionals from taking into full and careful consideration the relevant official updated recommendations or guidelines issued by the competent public health authorities, in order to manage each patient’s case in light of the scientifically accepted data pursuant to their respective ethical and professional obligations. It is also the health professional’s responsibility to verify the applicable rules and regulations relating to drugs and medical devices at the time of prescription.","PeriodicalId":11859,"journal":{"name":"Eurasian heart journal","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-12-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77821674","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-12-21DOI: 10.38109/2225-1685-2022-4-68-73
M. K. Barkovskaya, Z. Valieva, D. I. Darensky, A. Tereschenko, T. Martynyuk
The case of a 81-year-old male with atrial fibrillation, associated with severe aortic stenosis (AS) is outlined. A peculiarity of the clinical portrait of AS is a long asymptomatic period with a significantly varying duration. After the appearance of the first clinical manifestations of the disease (shortness of breath on exercise, fainting) the risk of sudden death rises sharply, and the average life expectancy is 2-3 years. The development of atrial fibrillation (AF) leads to a serious impairment of the clinical condition due to loss of the contribution of atrial systole to the filling of the left ventricle (LV). Concentric hypertrophy of the LV, which at the first stage is an important adaptation mechanism compensatingfor a high intracavitary pressure, later leads to a relative reduction of the coronary blood flow and to limitation of the coronary vasodilatation reserve. So patient was referred for transcatheter aortic valve implantation. He had also a history of coronary artery disease with earlier percutaneous coronary intervention. Then, he was started on a triple antithrombotic therapy therapy. The triple antithrombotic therapy caused gastrointestinal bleeding (Mallory-Weiss syndrome). Considering the difficulties in the rational choice of anticoagulant therapy and high risks of adverse reactions, the patient underwent endovascular occlusion of the left atrial appendage.
{"title":"Case report of transcatheter aortic valve implantation to the patient with severe aortic stenosis, atrial fibrillation, endovascular occlusion of the left atrial appendage and Mallory-Weiss syndrome","authors":"M. K. Barkovskaya, Z. Valieva, D. I. Darensky, A. Tereschenko, T. Martynyuk","doi":"10.38109/2225-1685-2022-4-68-73","DOIUrl":"https://doi.org/10.38109/2225-1685-2022-4-68-73","url":null,"abstract":"The case of a 81-year-old male with atrial fibrillation, associated with severe aortic stenosis (AS) is outlined. A peculiarity of the clinical portrait of AS is a long asymptomatic period with a significantly varying duration. After the appearance of the first clinical manifestations of the disease (shortness of breath on exercise, fainting) the risk of sudden death rises sharply, and the average life expectancy is 2-3 years. The development of atrial fibrillation (AF) leads to a serious impairment of the clinical condition due to loss of the contribution of atrial systole to the filling of the left ventricle (LV). Concentric hypertrophy of the LV, which at the first stage is an important adaptation mechanism compensatingfor a high intracavitary pressure, later leads to a relative reduction of the coronary blood flow and to limitation of the coronary vasodilatation reserve. So patient was referred for transcatheter aortic valve implantation. He had also a history of coronary artery disease with earlier percutaneous coronary intervention. Then, he was started on a triple antithrombotic therapy therapy. The triple antithrombotic therapy caused gastrointestinal bleeding (Mallory-Weiss syndrome). Considering the difficulties in the rational choice of anticoagulant therapy and high risks of adverse reactions, the patient underwent endovascular occlusion of the left atrial appendage.","PeriodicalId":11859,"journal":{"name":"Eurasian heart journal","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-12-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75655502","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-12-20DOI: 10.38109/2225-1685-2022-4-74-81
S. A. Musashaykhova, Z. Valieva, A. Osokina, I. Korobkova, V. Gramovich, N. Danilov, T. Martynyuk
Modern pathogenetic therapy of idiopathic pulmonary arterial hypertension (IPAH), a severe life-threatening cardiovascular disease of unknown etiology, leads to a positive clinical effect due to reverse remodeling of the vessels of the microvasculature of the lungs. Highly effective drugs of specific therapy that act on the main targets of pathogenesis have now been introduced into clinical practice.The presented clinical case of a patient with diagnosed in 2014 IPAH with an initial functional class III according to the WHO classification demonstrates high long-term efficacy and safety of specific therapy based on the use of the soluble guanylate cyclase stimulator riociguat for 5 years after replacing previous therapy with sildenafil with further implementation of the strategy of sequential combination therapy due to the addition of ambrisentan and selexipag.
{"title":"Possibilities of long-term effective treatment of idiopathic pulmonary arterial hypertension by replacing sildenafil with riociguat and using sequential combination therapy: case report","authors":"S. A. Musashaykhova, Z. Valieva, A. Osokina, I. Korobkova, V. Gramovich, N. Danilov, T. Martynyuk","doi":"10.38109/2225-1685-2022-4-74-81","DOIUrl":"https://doi.org/10.38109/2225-1685-2022-4-74-81","url":null,"abstract":"Modern pathogenetic therapy of idiopathic pulmonary arterial hypertension (IPAH), a severe life-threatening cardiovascular disease of unknown etiology, leads to a positive clinical effect due to reverse remodeling of the vessels of the microvasculature of the lungs. Highly effective drugs of specific therapy that act on the main targets of pathogenesis have now been introduced into clinical practice.The presented clinical case of a patient with diagnosed in 2014 IPAH with an initial functional class III according to the WHO classification demonstrates high long-term efficacy and safety of specific therapy based on the use of the soluble guanylate cyclase stimulator riociguat for 5 years after replacing previous therapy with sildenafil with further implementation of the strategy of sequential combination therapy due to the addition of ambrisentan and selexipag.","PeriodicalId":11859,"journal":{"name":"Eurasian heart journal","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78872647","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-12-20DOI: 10.38109/2225-1685-2022-4-82-89
E. Temnikova
According to international epidemiological studies, the total number of reported cases of cardiovascular diseases (CVD) almost doubled from 1990 to 2019, reaching 523 million and the number of deaths from CVD in 2019 increased by more than 1.5 times (18,6 million). Coronary artery disease (CAD) and stroke are the main contributors to these unfavorable trends. The number of registered cases of coronary heart disease in 2019 amounted to 197 million, and the number of deaths caused by coronary artery disease exceeded half of all registered cases of cardiovascular death (9,14 million). Patients with stable angina are the majority of patients with CAD. Despite the existing modern methods of treating angina pectoris, patients with chronic coronary artery disease continue to suffer from anginal pain, which significantly reduces exercise tolerance and worsens their quality of life. In clinical practice, the severity and frequency of angina pectoris in patients remain underestimated by doctors, and drug therapy is not corrected in a timely manner, and the possibilities of combined antianginal therapy are not used. Trimetazidine, as an antianginal drug that acts on the metabolism of ischemic myocardial cells (influence on the ischemic cascade, by reducing cellular acidosis and increasing ATP content), is effective and safety for the treatment of angina pectoris, regardless of the mechanism that caused ischemia as monotherapy and in the combination, primarily with beta-blockers.
{"title":"Pharmacological treatment of stable angina pectoris: the place of trimetazidine","authors":"E. Temnikova","doi":"10.38109/2225-1685-2022-4-82-89","DOIUrl":"https://doi.org/10.38109/2225-1685-2022-4-82-89","url":null,"abstract":"According to international epidemiological studies, the total number of reported cases of cardiovascular diseases (CVD) almost doubled from 1990 to 2019, reaching 523 million and the number of deaths from CVD in 2019 increased by more than 1.5 times (18,6 million). Coronary artery disease (CAD) and stroke are the main contributors to these unfavorable trends. The number of registered cases of coronary heart disease in 2019 amounted to 197 million, and the number of deaths caused by coronary artery disease exceeded half of all registered cases of cardiovascular death (9,14 million). Patients with stable angina are the majority of patients with CAD. Despite the existing modern methods of treating angina pectoris, patients with chronic coronary artery disease continue to suffer from anginal pain, which significantly reduces exercise tolerance and worsens their quality of life. In clinical practice, the severity and frequency of angina pectoris in patients remain underestimated by doctors, and drug therapy is not corrected in a timely manner, and the possibilities of combined antianginal therapy are not used. Trimetazidine, as an antianginal drug that acts on the metabolism of ischemic myocardial cells (influence on the ischemic cascade, by reducing cellular acidosis and increasing ATP content), is effective and safety for the treatment of angina pectoris, regardless of the mechanism that caused ischemia as monotherapy and in the combination, primarily with beta-blockers.","PeriodicalId":11859,"journal":{"name":"Eurasian heart journal","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84633056","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-11-22DOI: 10.38109/2225-1685-2016-3-42-210
A. Editorial
.
．
{"title":"ABSTRACTS OF THE IV EURASIAN CONGRESS OF CARDIOLOGISTS. October 10–11, 2016, Yerevan, Armenia","authors":"A. Editorial","doi":"10.38109/2225-1685-2016-3-42-210","DOIUrl":"https://doi.org/10.38109/2225-1685-2016-3-42-210","url":null,"abstract":"<jats:p>.</jats:p>","PeriodicalId":11859,"journal":{"name":"Eurasian heart journal","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-11-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86324747","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-10-12DOI: 10.38109/2225-1685-2022-3-90-96
T. D. Solnceva, A. A. Lachugin, O. Sivakova, I. Chazova
The purpose. Assessment of the presence of the cardiovascular risk factors, associated clinical conditions, the degree of target organ damage in patients with arterial hypertension depending on the new coronavirus infection. Material and methods. In a retrospective cohort study 284 patients with arterial hypertension were identified, 162 of them had a novel coronavirus infection and 122 patients didn’t have a history of a new coronavirus infection. Patients who had a new coronavirus infection were divided into groups depending on the disease. Inclusion criteria were the presence of arterial hypertension in history and taking antihypertensive therapy. Results. Patients with hypertension who’ve had a new coronavirus infection are more likely to have risk factors such as smoking, overweight, early menopause as opposed to patients with hypertension without indication of past COVID-19. Comparing patients with increased severity of the novel coronavirus infection elevated uric acid levels and hypercholesterolemia were associated with more severe COVID-19 (p < 0.05). Patients with chronic kidney disease, cerebrovascular disease, detection of atherosclerotic lesions of the brachiocephalic arteries and diabetes mellitus have an increased probability of deaths occur from the novel coronavirus infection (p < 0.05). There was no significant difference between the compared groups of coronary heart disease, atrial fibrillation, chronic heart failure and also the daily blood pressure profile and a severe course of COVID-19. Сonclusion. The presence of diabetes mellitus, cerebrovascular disease, chronic kidney disease, detection of atherosclerotic lesions of the brachiocephalic arteries, and also hyperuricemia or hypercholesterolemia in patients with hypertension revealed a risk of severe coronavirus infection.
{"title":"Features of the manifestation of arterial hypertension in patients with a new coronavirus infection","authors":"T. D. Solnceva, A. A. Lachugin, O. Sivakova, I. Chazova","doi":"10.38109/2225-1685-2022-3-90-96","DOIUrl":"https://doi.org/10.38109/2225-1685-2022-3-90-96","url":null,"abstract":" The purpose. Assessment of the presence of the cardiovascular risk factors, associated clinical conditions, the degree of target organ damage in patients with arterial hypertension depending on the new coronavirus infection. Material and methods. In a retrospective cohort study 284 patients with arterial hypertension were identified, 162 of them had a novel coronavirus infection and 122 patients didn’t have a history of a new coronavirus infection. Patients who had a new coronavirus infection were divided into groups depending on the disease. Inclusion criteria were the presence of arterial hypertension in history and taking antihypertensive therapy. Results. Patients with hypertension who’ve had a new coronavirus infection are more likely to have risk factors such as smoking, overweight, early menopause as opposed to patients with hypertension without indication of past COVID-19. Comparing patients with increased severity of the novel coronavirus infection elevated uric acid levels and hypercholesterolemia were associated with more severe COVID-19 (p < 0.05). Patients with chronic kidney disease, cerebrovascular disease, detection of atherosclerotic lesions of the brachiocephalic arteries and diabetes mellitus have an increased probability of deaths occur from the novel coronavirus infection (p < 0.05). There was no significant difference between the compared groups of coronary heart disease, atrial fibrillation, chronic heart failure and also the daily blood pressure profile and a severe course of COVID-19. Сonclusion. The presence of diabetes mellitus, cerebrovascular disease, chronic kidney disease, detection of atherosclerotic lesions of the brachiocephalic arteries, and also hyperuricemia or hypercholesterolemia in patients with hypertension revealed a risk of severe coronavirus infection.","PeriodicalId":11859,"journal":{"name":"Eurasian heart journal","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-10-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86147276","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-10-12DOI: 10.38109/2225-1685-2022-3-84-88
A. Vasin, O. Mironova, V. Fomin
Aim. The aim of our study was to assess the frequency of contrast-induced acute kidney injury (CI-AKI) in patients undergoing computed tomography (CT) with intravenous contrast media and to evaluate the effects of statins in the prevention of CI-AKI. Materials and methods. 181 patients undergoing CT with intravenous contrast media administration were included in prospective observational study (ClinicalTrials.gov ID NCT04666389). The primary endpoint was CI-AKI according to KDIGO criteria (the 25 % rise (or 0,5 mg/dl) of serum creatinine from baseline assessed 48–72 hours after administration of contrast media). There were 120 patients in the group with high dose of statins administration and 60 patients without statin treatment. The most frequent cardiovascular disease was hypertension in both groups — 93 % and 85 % respectively. Results. CI-AKI was diagnosed in 12 (6,7 %) patients — 9 patients in the no statins group and 3 patients in the statins group. The high dose statin administration statistically significant had less frequency of CI-AKI (p = 0,003) compare with no statins group (OR = 0,144, 95 %CI: 0,037–0,554). Conclusion. Statin pretreatment is effective at preventing CI-AKI and should be considered in high-risk patients.
{"title":"Intravenous contrast induced acute kidney injury prevention with high doses of statins","authors":"A. Vasin, O. Mironova, V. Fomin","doi":"10.38109/2225-1685-2022-3-84-88","DOIUrl":"https://doi.org/10.38109/2225-1685-2022-3-84-88","url":null,"abstract":" Aim. The aim of our study was to assess the frequency of contrast-induced acute kidney injury (CI-AKI) in patients undergoing computed tomography (CT) with intravenous contrast media and to evaluate the effects of statins in the prevention of CI-AKI. Materials and methods. 181 patients undergoing CT with intravenous contrast media administration were included in prospective observational study (ClinicalTrials.gov ID NCT04666389). The primary endpoint was CI-AKI according to KDIGO criteria (the 25 % rise (or 0,5 mg/dl) of serum creatinine from baseline assessed 48–72 hours after administration of contrast media). There were 120 patients in the group with high dose of statins administration and 60 patients without statin treatment. The most frequent cardiovascular disease was hypertension in both groups — 93 % and 85 % respectively. Results. CI-AKI was diagnosed in 12 (6,7 %) patients — 9 patients in the no statins group and 3 patients in the statins group. The high dose statin administration statistically significant had less frequency of CI-AKI (p = 0,003) compare with no statins group (OR = 0,144, 95 %CI: 0,037–0,554). Conclusion. Statin pretreatment is effective at preventing CI-AKI and should be considered in high-risk patients.","PeriodicalId":11859,"journal":{"name":"Eurasian heart journal","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-10-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88628860","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-10-12DOI: 10.38109/2225-1685-2022-3-66-72
S. H. Hamidov, A. Obrezan, P. S. Lobanova, S. V. Azarenko
This work is devoted to a literature review of published articles, where studies are focused on studying the frequency, structure of complications of cardiovascular diseases in patients with COVID-19, that occurred in vivo and post-mortem: myocarditis, myocardial damage, AMI, and other thrombotic events. Some studies also provide comparative data on COVID-19+ and COVID-19- patients, complication patterns, and mortality rates. The results of the studied materials shows that, the frequency of cardiac complications and the number of deaths are significantly more common in patients with concomitant diseases such as arterial hypertension, diabetes mellitus, obesity, CKD, arrhythmias. Patients over 60 years of age are at increased risk of a severe course of the disease, this is due to the fact that these individuals have concomitant chronic diseases that are decompensated due to an acute infectious process, reducing the adaptive capabilities of the organism, and lead to a deterioration in survival rates.
{"title":"Features of myocardial damage at COVID-19","authors":"S. H. Hamidov, A. Obrezan, P. S. Lobanova, S. V. Azarenko","doi":"10.38109/2225-1685-2022-3-66-72","DOIUrl":"https://doi.org/10.38109/2225-1685-2022-3-66-72","url":null,"abstract":" This work is devoted to a literature review of published articles, where studies are focused on studying the frequency, structure of complications of cardiovascular diseases in patients with COVID-19, that occurred in vivo and post-mortem: myocarditis, myocardial damage, AMI, and other thrombotic events. Some studies also provide comparative data on COVID-19+ and COVID-19- patients, complication patterns, and mortality rates. The results of the studied materials shows that, the frequency of cardiac complications and the number of deaths are significantly more common in patients with concomitant diseases such as arterial hypertension, diabetes mellitus, obesity, CKD, arrhythmias. Patients over 60 years of age are at increased risk of a severe course of the disease, this is due to the fact that these individuals have concomitant chronic diseases that are decompensated due to an acute infectious process, reducing the adaptive capabilities of the organism, and lead to a deterioration in survival rates.","PeriodicalId":11859,"journal":{"name":"Eurasian heart journal","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-10-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82519751","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：